Tessa Therapeutics’ $80 Million Financing Round


Wilson Sonsini Goodrich & Rosati represented Temasek on U.S. matters in the transaction

Tessa Therapeutics, an international biopharmaceutical company focused on T-cell therapy for solid tumors, completed an $80 million Series A round of financing led by Temasek.

The company, led by Andrew Khoo, Desmond Lim and Jennifer Butler, was incorporated in 2011 and is based in Singapore.

The investment will be used to further advance Tessa’s clinical pipeline and to bring new therapies, based on the company’s Virus Specific T-cell (VST) platform, into clinical trials.

The WSGR team representing Temasek in the transaction was led by partners Barry Taylor (Picture), Michael Rabson, and Sriram Krishnamurthy, and associates Christopher W. McAndrew, Jon Nygaard, and Shira Oyserman.

Involved fees earner: Barry Taylor – Wilson Sonsini Goodrich & Rosati; Jon Nygaard – Wilson Sonsini Goodrich & Rosati; Shira Oyserman – Wilson Sonsini Goodrich & Rosati; Michael Rabson – Wilson Sonsini Goodrich & Rosati; Christopher McAndrew – Wilson Sonsini Goodrich & Rosati; Sriram Krishnamurthy – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: Tessa Therapeutics Pte Ltd;

Print Friendly, PDF & Email
Avatar

Author: Ambrogio Visconti